214 related articles for article (PubMed ID: 30742095)
1. Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.
Yang J; Guo Y; Lu C; Zhang R; Wang Y; Luo L; Zhang Y; Chu CH; Wang KJ; Obbad S; Yan W; Li X
Oncogene; 2019 Jun; 38(24):4700-4714. PubMed ID: 30742095
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
3. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
Zhang Y; Li KF
Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
[TBL] [Abstract][Full Text] [Related]
4. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Zhu ZC; Liu JW; Yang C; Li MJ; Wu RJ; Xiong ZQ
Cell Death Dis; 2019 Feb; 10(2):118. PubMed ID: 30742128
[TBL] [Abstract][Full Text] [Related]
5. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Yoshino H; Sato Y; Nakano M
Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
[TBL] [Abstract][Full Text] [Related]
6. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells.
Stelma T; Leaner VD
Oncotarget; 2017 May; 8(20):32833-32847. PubMed ID: 28427184
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
8. KPNB1-mediated nuclear import in cancer.
Shi Q; Lin M; Cheng X; Zhang Z; Deng S; Lang K; Yang Z; Sun X
Eur J Pharmacol; 2023 Sep; 955():175925. PubMed ID: 37473981
[TBL] [Abstract][Full Text] [Related]
9. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; Tien JC; Rangel R; Hashimoto K; Mabuchi S; Sawada K; Kimura T; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7301-E7310. PubMed ID: 28811376
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
11. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
14. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
15. Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis.
Li J; Zhang B; Feng Z; An D; Zhou Z; Wan C; Hu Y; Sun Y; Wang Y; Liu X; Wei W; Yang X; Meng J; Che M; Sheng Y; Wu B; Wen L; Huang F; Li Y; Yang K
J Exp Clin Cancer Res; 2024 Jan; 43(1):28. PubMed ID: 38254206
[TBL] [Abstract][Full Text] [Related]
16. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W; Li R; He J; Du J; Hou J
Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
[TBL] [Abstract][Full Text] [Related]
18. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of KPNB1 Inhibits Proliferation and Promotes Apoptosis of Chronic Myeloid Leukemia Cells Through Regulation of E2F1.
Wang T; Huang Z; Huang N; Peng Y; Gao M; Wang X; Feng W
Onco Targets Ther; 2019; 12():10455-10467. PubMed ID: 31819526
[TBL] [Abstract][Full Text] [Related]
20. Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
Wang J; Yang ZH; Chen H; Li HH; Chen LY; Zhu Z; Zou Y; Ding CC; Yang J; He ZW
BMC Cancer; 2016 Mar; 16():257. PubMed ID: 27036119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
